solvent or diluent such as an alcohol (e.g., methanol or ethanol) or an ether ( e.g., IBF). The pH of aqueous mixtures is typically in a range of from about 1 to about 7. The temperature of the mixture is suitably maintained in a range of from about 15 to about 30° C. (e.g., about 25° C.). In a typical procedure, Compound I is mixed with an aqueous or organic suspension of the cation exchange resin. The adsorp› tion of drug onto the resin can be detected by measuring a change in the pH of an aqueous medium, or by measuring a change in concentration of the counterion (sodium) or of Compound I. The resulting Compound I-resin complex is collected and washed (e.g., with alcohol and/or water) to insure removal of any unbound drug. The resin complex can then be air- or vacuum- dried at room or elevated tempera› ture. Further description of techniques for adsorption of a drug onto the cation exchange resin particles can be found in the art, for example, in U.S. Pat. No. 2,990,332 and U.S. Pat. No. 4,221,778, both of which are herein incorporated by reference in their entireties. 

[0301] Binding of drug to resin can be accomplished according to four general reactions: (a) resin (Na-form) plus drug (salt form); (b) resin (Na-form) plus drug (as free base); (c) resin (H-form) plus drug (salt form); and (d) resin (H-form) plus drug (as free base). All of these reactions except (d) have cationic by-products, which compete with the cationic form of Compound I for binding sites on the resin and thus can reduce the amount of drug bound at equilibrium. Stoichiometric binding of drug to resin can be accomplished through reaction (d). The binding may be performed, for example, as a batch or column process, as is known in the art. 

[0302] The complex typically has a weight ratio of Com› pound I to resin in the range of from about 1: 10 to about 10: 1 (e.g., from about 1:5 to about 5:1 or from about 1:3 to about 3:1) and more typically from about 1:2 to about 2:1 (e.g., about 1:1). 

[0303] The amount of the Compound I complexed with the ion exchange resin is suitably in the range from about 15 to about 80% by weight of the Compound I-resin complex, and is typically in the range of from about 20 to about 70% by weight of the Compound I-resin complex. In one aspect of the invention, the amount of Compound I complexed to the ion exchange resin is in the range from about 25 to about 50% by weight of the Compound I-resin complex. 

[0304] The Compound I-cation exchange resin complex is suitably administered orally. The complex will enter the acidic environment of the stomach (pH of about 2 to 3), wherein the ionized form of Compound I (e.g., ammonium) can be ion exchanged with other cations found in the stomach (e.g., H+). Due to a concentration gradient, the exchanged Compound I cation is released from the poly› meric support and will diffuse out of the resin. Compound I can then be absorbed and enter the circulation. 

[0305] Suitable forms for oral administration include liq› uid forms such as a suspension and solid forms such as a tablet or capsule. A tablet can be obtained by directly compressing the resin complex of the invention, which can be in the form of granules, with one or more excipients such 

as diluents, binders, lubricants, glidants, disintegrants, col› oring agents and flavoring agents. Excipients suitable for use in preparing the present invention in tablet form include th~hse described in Remington’s Pharmaceutical Sciences, 18 edition, 1990, pp. 1635-1638, which is herein incorpo› rated by reference in its entirety. A granule is a solid preparation comprising small particles containing the Com› pound I-resin complex of the invention and one or more excipients such as lactose, mannitol, microcrystalline cellu› lose or talc. The granules can be prepared by wet or dry granulation techniques known in the art. A capsule is a container, such as a gelatin shell, for the resin complex of the invention, and can be a dry-filled, wet-filled, liquid-filled or granule-filled shell. A solid form can be of different shapes, sizes or colors depending, for example, on the type and amount of Compound I-resin complex and the excipients (if any) it contains. 

[0306] Compound I can be administered orally to humans in a dosage range of 0.001 to 1000 mg/kg body weight in divided doses. One preferred dosage range is 0.1 to 200 mg/kg body weight orally in divided doses. Another pre› ferred dosage range is 0.5 to 100 mg/kg body weight orally in divided doses. For oral administration, the compositions of the present invention are preferably provided in the form of capsules or tablets containing 1 to 1000 milligrams of the active ingredient, particularly 1, 5, 10, 15. 20, 25, 50, 75, 100,150,200,250,300,400,500,600,750,800,900, and 1000 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy. 

[0307] Oral administration to human subjects suitably follows a meal or a soda, which typically will increase stomach acidity and thus promote release of the drug from the resin. 

[0308] In a preferred embodiment, the oral dosage form is a capsule containing from about 10 to about 1000 mg of Compound I complexed with a cation exchange resin. In one aspect of this embodiment, the cation exchange resin is Amberlite IRP-69, wherein the amount of Compound I complexed with the resin is in the range from about 15 to about 75% by weight of the Compound I-resin complex. 

[0309] The present invention also includes combinations of the composition of the invention comprising the Com› pound I-cation exchange resin complex with one or more agents useful in the treatment of HIV infection and/or AIDS. For example, the compounds of this invention may be effectively administered in combination with effective amounts of the HIV/AIDS antivirals, imunomodulators, antiinfectives, or vaccines, such as those in Table 1 as follows: 

